Doximity Aktie News

Doximity's Q2 results show record engagement and accelerating adoption of AI workflow tools, signaling deeper physician reliance on the platform. Revenue quality is improving as pharma clients shift from one-off ad buys to longer-term integrated programs. Doximity has a strong Rule-of-50 profile with high margins and $890m cash but no debt.

CVNA last traded at $313.25 a share after finding support at $285.02, which was double-bottom support dating back to June 2025.

Doximity, Inc. ( DOCS ) Q2 2026 Earnings Call November 6, 2025 5:00 PM EST Company Participants Perry Gold - Head of Investor Relations Jeffrey Tangney - Co-Founder, CEO & Chairperson Anna Bryson - Chief Financial Officer Conference Call Participants Brian Peterson - Raymond James & Associates, Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Allen Lutz - BofA Se...

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30, 2025. “Our platform continues to grow with new AI tools to save physicians' time,” said Jeff Tangney, co-founder and CEO of Doximity. “In Q2, a record 650,000 prescribers used our workflow tools to...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. If you currently own Doximity stock and acquired shares on or before June 24, 2021, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-a...

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2025 after market close on November 6, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a liv...

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors. Investors who have continuously held Doximity shares since before June 24, 2021, may have legal rights and are encouraged to contact the ...

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors. Investors who have continuously held Doximity shares since before June 24, 2021, may have legal rights and are encouraged to contact the ...